New drugs don’t appear out of thin air

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

On Saturday, Dec. 21, Congress passed a new spending package, narrowly averting a government shutdown.

January 10, 2025

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

In Brief

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

OmniaBio Inc. announced the opening of a new North American cell and gene therapy manufacturing and artificial intelligence center of excellence, which is now Canada’s largest contract development and manufacturing organization facility dedicated to CGT.

October 25, 2024

Vol.50 No.40

In Brief

Alex Morozov named chief medical officer at Pi Health

Alex Morozov was named the first chief medical officer of Pi Health, an oncology clinical trial and research technology company.

August 09, 2024

Vol.50 No.32

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

August 02, 2024

Vol.50 No.31

By Donald A. Berry

New drugs don’t appear out of thin air

YOU MAY BE INTERESTED IN

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

Alex Morozov named chief medical officer at Pi Health

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Renew today!

Subscriber content

Never miss an issue!

Login

New drugs don’t appear out of thin air

YOU MAY BE INTERESTED IN

Pediatric cancer research cut from spending legislation at last minuteRepublicans quietly removed hard-won pediatric cancer bills

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

Alex Morozov named chief medical officer at Pi Health

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

Never miss an issue!

Login

Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC